Tentative, subject to change
1:00 p.m. | Registration
1:30 p.m. | Welcome Remarks
- Uciane Scarlett – Principal, MPM BioImpact
- Tom Murtagh – Global Practice Lead, Strategy & Insight, Lumanity
1:40 p.m. | Research fire-side chat: State of the Scientific Landscape
- Shawn M. Sweeney, PhD – Senior Director, AACR Project GENIE Coordinating Center
- Moderator: Uciane Scarlett – Principal, MPM BioImpact
2:20 p.m. | Innovation Bridge presentation: Title TBD
- Dennis Chang – Managing Director, Lumanity
- Jeffrey Bockman – EVP, Head of Oncology, Lumanity
2:45 p.m. | Innovation debate-style panel: How much complexity is necessary? How much is feasible?
- Anthony Letai, MD, PhD – Professor, DFCI; Co-founder of Vivid Biosciences
- Ben Auspitz – Founding Partner, Forge Life Science Partners
- Detlev Biniszkiewicz, PhD - Managing Director, MPM BioImpact, CEO, NextPoint
- Joanne Lager, MD - CMO, NiKang Therapeutics Inc.
- Kapil Dhingra, MD – Former Head, Roche Oncology
- Keith Flaherty, MD – Professor, MGH; co-founder, Apricity, C-Reveal, Loxo, Scorpion, Strata, X4
- Moderator: Prashant Girinath – Partner, Greenberg Traurig
3:45 p.m. | Break
3:50 p.m. | People round table: Talent requirements for precision oncology in the future
- Catherine Sabatos-Peyton, PhD – CEO, Larkspur Biosciences
- Francesca Barone, MD, PhD – CSO, Candel Therapeutics
- Frank Stegmeier, PhD – CSO Partner, Curie.Bio
- Melissa McCracken, PhD – Partner, Nextech Invest
- Moderator: Luke Timmerman – Founder, Editor, Timmerman Report
4:50 p.m. | Closing Remarks
- Luke Timmerman – Founder, Editor, Timmerman Report
- Yung Lie, PhD – President & CEO, Damon Runyon Cancer Research Foundation
- Martin Strebl-Bantillo – Principal, Lumanity
5:00 – 7:30 p.m. | Reception sponsored by MPM BioImpact